SLC6A1-NDD Prospective Longitudinal Natural History Study
Part of paid clinical trials in New York, New York.
- Sponsor
- UCB Biopharma SRL
- Study ID
- NCT07531511
- Status
- Recruiting
Conditions
- Developmental and Epileptic Encephalopathies (DEE)
- SLC6A1 Neurodevelopmental Disorder (NDD)
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - 17 Years
- Healthy Volunteers
- Not accepted
Study Details
The overall objective of this prospective longitudinal natural history study is to collect clinical data to characterize and evaluate the natural course of SLC6A1-NDD and assess the feasibility of certain assessments for the purpose of conducting future clinical studies in patients with this disease.
Key Dates
- First listed
- Apr 15, 2026
- Start date
- Jul 21, 2026
- Status verified
- Jul 2026
- Primary completion
- May 25, 2029
- Completion
- May 25, 2029
Study Design
- Enrollment
- 60 participants (estimated)
Arms
- Arm: Age group 1 (< 6 years)This age group consists of patients which are \< 6 years at the time of study enrollment.
- Arm: Age group 2 (6 to 17 years)This age group consists of patients which are between 6 and 17 years at the time of study enrollment.
Primary Outcome Measure
Seizure frequency by type (countable seizures per 28 days) by visit as compared to Baseline [ Time Frame: 2 years ]
Central Contacts
- UCB Cares+18445992273
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Gtep01 50614 | New York | New York | 10021 | - |
Find similar trials in New York, NY
By research site